Cleveland BioLabs, Inc. logo
Cleveland BioLabs, Inc. CBLI

Cleveland BioLabs, Inc. EBITDA 2011-2026 | CBLI

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Cleveland BioLabs, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-2.58 M -2.35 M -4.78 M -5.58 M -6.29 M -10.7 M -14.2 M -22.6 M -29.6 M -24.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-2.35 M -29.6 M -12.3 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
3.11 B - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
1.19 M $ 0.89 - $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
31.8 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
232 M $ 22.2 - $ 3.68 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
-6.83 M $ 15.9 - $ 50.8 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-124 M - - $ 10.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
-31 M $ 0.76 - $ 27.9 M israelIsrael
Exelixis Exelixis
EXEL
901 M $ 44.69 - $ 12.1 B usaUSA
Advaxis Advaxis
ADXS
-35.9 M - -9.65 % $ 45.9 M usaUSA
Galapagos NV Galapagos NV
GLPG
-166 M $ 27.86 - $ 2.69 B belgiumBelgium
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Grifols, S.A. Grifols, S.A.
GRFS
595 M $ 7.91 - $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
232 M $ 31.05 - $ 1.79 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-8.67 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
-23.9 M - -10.17 % $ 12.2 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
4.43 M $ 8.44 - $ 76.2 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-9.75 M - -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
15.3 B $ 101.57 - $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
Immuron Limited Immuron Limited
IMRN
-2.87 M $ 0.81 0.3 % $ 9.47 M australiaAustralia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
Incyte Corporation Incyte Corporation
INCY
1.61 B $ 99.1 - $ 19.3 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
-55.6 M - 1.93 % $ 17.4 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
-7.75 M $ 0.7 - $ 1.71 M canadaCanada
INmune Bio INmune Bio
INMB
-47.3 M $ 1.33 - $ 32.9 M usaUSA
Innoviva Innoviva
INVA
190 M $ 23.05 - $ 1.55 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
-47.8 M $ 1.48 -0.67 % $ 235 M franceFrance
Jaguar Health Jaguar Health
JAGX
-44 M $ 7.88 - $ 18.4 M usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
-190 M - - $ 28.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
-111 M $ 26.67 - $ 1.44 B britainBritain
AlloVir AlloVir
ALVR
-46.1 M - 4.14 % $ 49.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
-696 K $ 8.11 - $ 260 M israelIsrael
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-9.93 M $ 2.98 - $ 4.91 M israelIsrael
Krystal Biotech Krystal Biotech
KRYS
167 M $ 259.95 - $ 7.52 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
-7.74 M $ 12.42 - $ 1.65 B australiaAustralia
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
12.6 M $ 224.86 - $ 4.11 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
122 K - -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
-412 M - - $ 867 M germanyGermany
Liquidia Corporation Liquidia Corporation
LQDA
-49.8 M $ 38.15 - $ 3.28 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-64.5 M - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
22 K - -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
-70.5 M $ 4.05 - $ 433 M usaUSA
Aptinyx Aptinyx
APTX
-62.4 M - -39.0 % $ 4.57 M usaUSA